Engineering New Approaches to Cancer Vaccines by Irvine, D. J. et al.
Engineering new approaches to cancer vaccines
Naveen K. Mehta1,2, Kelly D. Moynihan1,2,4, and Darrell J. Irvine1,2,3,4,5,*
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 
Cambridge 2Department of Biological Engineering, Massachusetts Institute of Technology, 
Cambridge 3Department of Materials Science and Engineering, Massachusetts Institute of 
Technology, Cambridge 4Ragon Institute of MGH, MIT and Harvard University, Boston, 
Massachusetts 5Howard Hughes Medical Institute, Chevy Chase, Maryland
Abstract
Recently, a number of promising approaches have been developed using synthetic chemistry, 
materials science, and bioengineering-based strategies to address challenges in the design of more 
effective cancer vaccines. At the stage of initial priming, potency can be improved by maximizing 
vaccine delivery to lymph nodes. Because lymphatic uptake from peripheral tissues is strongly 
size-dependent, antigens and adjuvants packaged into optimally-sized nanoparticles access the 
lymph node with much greater efficiency than unformulated vaccines. Once primed, T cells must 
home to the tumor site. Because T cells acquire the necessary surface receptors in the local lymph 
node draining the tissue of interest, vaccines must be engineered that reach organs such as the lung 
and gut, which are common sites of tumor lesions but inaccessible by traditional vaccination 
routes. Particulate vaccine-carriers can improve antigen exposure in these organs, resulting in 
greater lymphocyte priming. Immunomodulatory agents can also be injected directly into the 
tumor site to stimulate a systemic response capable of clearing even distal lesions; materials have 
been designed that entrap or slowly release immunomodulators at the tumor site, reducing 
systemic exposure and improving therapeutic efficacy. Finally, lessons learned from the design of 
biomaterial-based scaffolds in regenerative medicine have led to the development of implantable 
vaccines that recruit and activate antigen presenting cells to drive anti-tumor immunity. Overall, 
these engineering strategies represent an expanding toolkit to create safe and effective cancer 
vaccines.
Motivation for cancer vaccine engineering
Therapeutic vaccination is one of the oldest and most studied concepts in cancer 
immunotherapy. Yet, in contrast to prophylactic vaccines against infectious disease, which 
have had a major impact on public health, therapeutic vaccines against cancer have 
generally been much less successful, and only a single cancer vaccine has been FDA 
approved to date (1, 2). This is likely due to a variety of factors, including a paucity of truly 
foreign antigens expressed by tumor cells, lack of infection-associated inflammatory cues 
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that drive productive immunity, chronic antigen exposure, the presence of a highly 
immunosuppressive microenvironment in solid tumors, and our as yet still poor 
understanding of how to induce strong and sustained T-cell-mediated immune responses in 
humans. However, there are at least three reasons why cancer vaccines should see renewed 
interest as part of the cancer immunotherapy armamentarium, based on recent rapid 
advances in the field: First, the advent of clinical-stage therapeutics that can directly 
influence the immunological status of the tumor microenvironment, such as checkpoint 
blockade antibodies (3), regulatory T-cell-modulating chemotherapy (4), and IDO inhibitors 
(5) (to name a few), now provide a number of ways to overcome immunosuppressive 
pathways in patients. Secondly, the availability of an ever-growing array of targeted drugs 
that can dramatically (but transiently) lower tumor burden provides a window of opportunity 
for vaccines to act in a setting of minimal disease, and some of these drugs may act 
synergistically with the immune response (6). Lastly, powerful genomic sequencing 
capabilities are enabling the possibility of patient-specific vaccines targeting defined 
neoantigens, which have the potential for alleviating the safety and efficacy challenges of 
targeting unmutated self antigens (7–9). Altogether, these recent developments in cancer 
therapy strongly motivate renewed efforts to develop effective therapeutic cancer vaccine 
approaches.
How might we enhance the vaccines themselves to enable therapeutic immunization to reach 
its full potential in this new era of cancer immunotherapy? First is the issue of vaccine 
potency, as measured by the number, functionality, and avidity of antigen-specific T-cells 
induced by cancer vaccines. A number of experimental and licensed infectious disease 
vaccines induce robust multifunctional CD4+ and CD8+ T-cell responses in humans that can 
be detected directly ex vivo and measured even by relatively low-sensitivity methods like 
peptide-MHC tetramer staining (10, 11). By contrast, with a few exceptions (12, 13), the 
response to cancer vaccines is often only robustly detected by expanding/stimulating patient 
T-cells over 1–2 weeks ex vivo (14–16) – a direct indicator of the low frequency of 
responding cells. These results may be partly due to issues of tolerance to self-antigens and 
systemic immunosuppression in cancer patients, but also may reflect the common use of 
minimal-epitope peptide vaccines and weak adjuvants which have known immunological 
shortcomings (17). Equally important is for vaccines to be capable of promoting T-cell 
responses enriched in high-avidity, polyfunctional T-cells with high proliferative capacity 
that avoid induction of an exhausted/terminally-differentiated phenotype. Finally, devising 
vaccine strategies that prime effective trafficking of effector cells to tumor sites is critical, 
which in cases such as mucosal tumors, could be directly influenced by vaccines that 
program expression of appropriate tissue homing receptors (18). Thus, a number of 
strategies exist to enhance current vaccine approaches to increase the efficacy of therapeutic 
anti-tumor immune responses.
There are many ways to improve therapeutic vaccines rooted in traditional vaccinology 
principles such as microbial vector development, molecular biology, and adjuvant design, 
but in this brief perspective, we will review promising recent preclinical and early clinical 
developments derived from approaches based in immune engineering–bringing methods 
from chemistry, chemical engineering, materials science, and biological engineering to bear 
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on the problem of therapeutic vaccine design. Such approaches are particularly well suited 
to augmenting vaccines based on subunit antigen (defined protein, peptide, or 
polysaccharide epitopes) and tumor cell lysate-based vaccines, and we focus on these two 
ubiquitous classes of cancer vaccine antigens.
Targeting vaccines to lymph nodes
A very basic issue in generating robust immunity with cancer vaccines is efficient delivery 
of vaccine components to lymphoid tissues, the sites of immune response orchestration. 
Nearly all vaccines are administered parenterally, either intramuscularly or subcutaneously. 
Following injection of soluble protein/peptide vaccines, antigen arrives in draining lymph 
nodes in two phases: first, lymph node-resident dendritic cells (DCs) directly access antigen 
as it drains through afferent ducts, and present antigen to T cells to initiate an immune 
response. This response is sustained during the second phase, when migratory DCs or 
monocytes that have phagocytosed additional antigen at the site of injection arrive in the 
lymph node (19). In some settings, however, only the first phase may be necessary: In mice 
vaccinated with protein antigens fused to an anti-CD205 antibody to target cross-presenting 
lymph node-resident DCs, migratory DC depletion actually enhanced T cell priming (20). 
Migratory DCs were shown to contain expression signatures enriched in genes associated 
with immune suppression, compared to cross-presenting lymph node-resident DCs. That 
lymph node delivery is key to vaccine potency is shown by studies of intra-lymph node 
injections, which demonstrated that peptide or DNA vaccines injected directly into LNs are 
100-fold more potent than the same vaccine administered subcutaneously (21, 22).
Although the fate of injected vaccines is a complex interplay of numerous parameters, the 
physical size of vaccine components– whether they be particulates or individual molecules– 
plays a significant role in determining the outcome, as shown in Figure 1A (23). Molecules 
or particles injected in tissue can be cleared by either entering the blood or the lymph. In 
classic studies in sheep comparing the biodistribution of a series of molecules of varying 
molecular weight from tissues following injection, Supersaxo and colleagues showed that 
large proteins preferentially convected to the lymph node rather than being lost to systemic 
circulation (24). This is because the lymphatic endothelium has valve-like openings enabling 
the entry of large particles, while the capillary endothelium is lined by an uninterrupted 
basement membrane that blocks the transit of large macromolecules. A linear correlation is 
observed between molecular weight and the fraction of lymph node (LN) uptake up to a 
threshold of 45 kDa (corresponding to a size of approximately 4–5 nm in diameter for a 
globular protein), at which point nearly 100% of protein is delivered to the lymph and 
downstream draining lymph node (25). Consistent with this finding, unformulated peptides 
(26), molecular adjuvants (26–28), and small protein antigens show very poor uptake in 
lymph nodes, and soluble small-molecule adjuvants often show significant systemic 
inflammatory toxicity (26–28). While both preclinical and clinical studies have often sought 
to solve this problem by administering vaccines in “depot”-based adjuvants such as 
incomplete Freund’s adjuvant, it has been shown that passive, non-inflammatory depots of 
antigen at the injection site become a decoy for effector cells that leads to deletion of the 
very T-cells that are meant to be primed by the vaccine (29).
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The size-dependent physiology of lymphatic trafficking has motivated studies of synthetic 
nanoparticles larger than individual proteins as carriers to efficiently deliver small antigens/
molecular adjuvants to the lymph node. Maximal lymph node targeting is a size 
optimization problem as particles that are larger than the average pore size in the 
extracellular matrix may become entrapped in the tissue rather than convecting to 
lymphatics. A series of studies by three different groups demonstrated that nanoparticles 
with diameters under ~50 nm target lymph nodes much more efficiently than larger 
particles. Reddy et al. injected labeled 20 nm, 45 nm, and 100 nm poly(propylene sulfide) 
nanoparticles intradermally and sampled the draining lymph nodes up to 120 hours later; 
while the 20 nm and 45 nm ultra-small nanoparticles were present in the lymph node 
throughout the time points sampled, 100 nm particles could not be detected (30). Manolova, 
et al. (31) and Fifis et al. (32) reached similar conclusions using virus-like particles or 
synthetic polystyrene nanoparticles of different sizes as carriers for vaccines, demonstrating 
that particles in the 20–40 nm size range were much more effective for lymph node delivery 
and subsequent vaccine responses than larger particles. Nanoparticles can also be used to 
deliver potent molecular adjuvants to lymph nodes, and promising data in both mice (28, 
33–38) and non-human primates (34, 39) suggests this is an approach that should be moved 
toward clinical testing, especially for small molecule adjuvants where such approaches can 
increase both the safety and potency. Finally, on arrival in lymph nodes, nanoparticles have 
the potential to impact multiple aspects of antigen processing and presentation by enabling 
antigen and adjuvant to be co-delivered into recipient antigen presenting cells (41), 
promoting cross presentation of antigen (33, 42), and acting as intracellular/extracellular 
vaccine depots (42, 43). An exciting recent study demonstrated a method to coat polymer 
nanoparticles with native tumor cell-derived plasma membranes, leading to cross 
presentation of tumor membrane-associated antigens, providing a means to combine 
complex tumor-derived antigen mixtures with particle-based lymph node targeting (44).
A second strategy to target vaccines to lymph nodes is to exploit reversible binding to 
proteins naturally meeting the size-dependent criteria for effective lymphatic uptake. For 
example, albumin, the most prevalent protein in blood and interstitial fluid, is a 66 KDa 
globular protein with a hydrodynamic diameter of approximately 5 nm– and thus traffics one 
way from the blood to the lymph in the interstitial space. Liu et al. conjugated peptide 
antigens and CpG adjuvant to saturated hydrocarbon lipid tails chosen to promote binding to 
fatty acid-binding pockets of albumin (26). Importantly, these conjugates were comprised of 
an albumin-binding tail linked to the antigen via a highly water soluble poly(ethylene 
glycol) (PEG) chain. This PEG spacer solubilized the conjugates and prevented the 
conjugate from stably inserting in cell membranes, an important distinction from traditional 
lipopeptide vaccines. Upon injection, these vaccine amphiphiles bound to albumin, leading 
to >10-fold increases in lymph node accumulation relative to the parent vaccine molecules. 
In therapeutic melanoma and cervical cancer tumor models, lipid-conjugated vaccines were 
able to significantly delay growth of established tumors at doses where traditional peptide/
adjuvant vaccines were completely ineffective.
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Vaccine-Mediated programming of T-cell homing to tumor sites
It has been observed in many clinical studies that the presence of circulating tumor antigen-
specific T-cells does not correlate with clinical outcome, and this is consistent with the 
expectation that activated T-cells must home to tumor sites to impact disseminated disease. 
Cancer vaccines can impact this phase of the immune response by ensuring induction of 
appropriate tissue-homing receptor profiles on newly primed tumor-specific lymphocytes, as 
seen in Figure 1B. A key strategy to control tissue-specific effector cell trafficking is via 
choice of vaccination site, because dendritic cells in lymph nodes draining different tissue 
sites express factors regulating the expression of tissue homing receptors on T-cells primed 
in these sites. Thus, T-cells primed in mediastinal lymph nodes express α4β1 integrins and 
home to the lungs; DCs in skin-draining lymph nodes induce T-cells to express cutaneous 
lymphocyte antigen (CLA) and CCR4 to home to the skin; and DCs of the gut-associated 
lymphoid tissues secrete retinoic acid, programming expression of α4β7 and CCR9 on T-
cells for homing to the gut lamina propria (45). While these tissue-specific homing patterns 
have all been defined in the setting of T-cell trafficking to normal tissues, they are also 
critical in the therapeutic setting of effector T-cells homing to tumor sites. For example, in 
orthotopic tumor models of head and neck and lung cancer, Sandoval, et al. demonstrated 
that mucosal, but not intramuscular, delivery of vaccines can promote CD8-mediated 
rejection of mucosal tumors (46). Human papillomavirus 16 E7-expressing TC-1 cells were 
engrafted in the submucosal lining of the tongue or in the lung as model mucosal tumors. 
Shiga toxin 1 subunit B (STxB) E7 fusions in combination with αGalCer adjuvant were 
administered intranasally or intramuscularly, and while both vaccines generated systemic 
CD8+ T-cell responses, intranasal delivery resulted in more efficient tumor clearance in both 
models. Mechanistically, this was traced to mucosal imprinting of activated antigen-specific 
T cells, as measured by CD49a and CD103 expression, which allowed for effective homing 
and infiltration at the tumor site. Thus, strategies to enhance local tissue immunization may 
have a significant impact on the efficacy of cancer vaccines.
To this end, nanoparticle formulations discussed above for parenteral immunization have 
also been shown to enhance vaccine antigen/adjuvant uptake across pulmonary and nasal 
mucosa, which could promote tumor-homing T-cell responses in the setting of lung 
carcinoma, head and neck cancer, and treatment of lung metastases in a variety of other 
cancers. Nanoparticles can co-deliver antigen and molecular adjuvants to dendritic cells in 
the airway mucosa and promote uptake by DCs prior to mucociliary clearance (36, 47, 48). 
For example, exploiting the high density of dendritic cells lining alveoli in the lungs, 
pulmonary vaccination with lipid nanocapsules carrying a protein antigen and Toll-like 
receptor agonists led to increased persistence of antigen in the lungs 24 hours after 
administration, and subsequently greatly increased trafficking of antigen to lung-draining 
lymph nodes several days later. This enhanced antigen delivery translated to >10-fold 
increases in T-cell priming compared to soluble forms of the same antigen and adjuvant, and 
enabled pulmonary nanocapsule vaccination to be 100% protective in a lung metastasis 
model, compared to only 20% protection in the equivalent soluble vaccine (49). In a similar 
vein, intranasal vaccination with antigen-carrying poly(γ-glutamic acid) nanoparticles 
enhanced therapeutic protection against melanoma lung metastases (50). Pulmonary 
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vaccination with PEGylated poly(propylene sulfide) nanoparticles conjugated to antigens 
using a reduction-sensitive linker combined with soluble CpG has been shown to enhance 
antigen uptake in lung-draining lymph nodes and subsequent lung-homing antigen specific 
T-cell populations (51, 52). Thus, several types of nanoparticle formulations have shown 
efficacy in enhancing mucosa-homing T-cell responses and mucosal anti-tumor immunity.
Analogous to pulmonary vaccination for protection of airway mucosal tissues, oral 
vaccination may facilitate anti-tumor immunity in the gastrointestinal tract, and could thus 
help protect against cancers of the throat, stomach, intestine, and colon. A non-obvious 
benefit of vaccinating the gastrointestinal tract is that T cell priming in the lymphoid organs 
of the large intestine can induce protection of rectal and vaginal mucosa, which are difficult 
to vaccinate directly (53). The design of effective oral vaccines that reach the large intestine 
has been challenging largely because of the low pH and destructive enzymatic activity 
characteristic of the gut. To solve this problem, Zhu et al. developed PLGA nanoparticles 
that encapsulated peptide antigen and three TLR agonists: MALP-2, poly(I:C), and CpG 
(53). These nanoparticles were subsequently encapsulated within anionic pH-responsive 
polymer capsules. The capsules were designed to have mean diameters > 10 μm to prevent 
non-specific phagocytosis and uptake by Peyer’s patches in the small intestine, and to 
dissolve at pH values greater than 7, characteristic of the terminal ileum of the large 
intestine, to allow for vaccine release only in this localized region of interest. Significantly 
stronger T cell responses in the large intestine were generated when capsules of appropriate 
pH responsiveness were used as a coating rather than an alternative polymer that dissolved 
at more acidic pH. This general delivery strategy may thus hold potential in the treatment of 
colorectal tumors and establishes a paradigm for targeting other regions of the GI tract. 
Together, these studies demonstrate that physically programmable properties of particulate 
vaccine carriers can be used to specifically target different organs to target the immune 
response to the required site of protection.
Exploiting the tumor site as an antigen source
A seminal observation in cancer immunology was Dr. William Coley’s discovery in 1893 
that repeated intratumoral injection of bacteria could induce tumor rejection. Nearly one 
hundred years later, trials in humans found that intratumoral administration of BCG in 
metastatic melanoma lesions resulted not only in the regression of 90% of the injected 
lesions, but also 17% of distal tumors (54). Although intratumoral injections of 
immunomodulators are intended to be local treatments, in many cases they can generate a 
systemic immune response capable of targeting distal tumors in a vaccine-like manner, 
turning the tumor itself into an in situ vaccine, as depicted in Figure 1C. Importantly, this 
strategy does not depend on the discovery of tumor-specific antigens, and instead exploits 
the tumor itself as a source of antigen.
Local administration of diverse immunostimulatory agents to an accessible lesion has been 
effective at promoting systemic tumor rejection in animal models and humans. For example, 
intratumoral injection of CpG, anti-OX40, and anti-CTLA4 in mouse lymphoma models can 
eradicate regulatory T-cells from tumors (55). In humans, topical application of a cream 
prepared with 5% imiquimod, a TLR7 agonist, has been shown to induce 80% histological 
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clearance in human patients with superficial basal cell carcinoma (56). In some cases, local 
administration of immunomodulators increases susceptibility to subsequent systemic 
therapy. In mouse melanoma models with tumors on both the right and left flank, Zamarin et 
al. showed that oncolytic virus injections into one tumor increased lymphocytic infiltration 
even in the contralateral tumor, improving the efficacy of systemically administered anti-
CTLA4 therapy (57). Analogously in humans, early clinical trials suggest that stereotactic 
body radiotherapy, where radiation is precisely delivered to tumor sites to enhance local 
inflammation, can improve responses to IL-2 therapy in patients with metastatic lesions 
(58). Despite the promise of intratumoral injections in promoting anti-tumor immunity, one 
deficiency in intratumoral administration of soluble therapeutics is that locally-applied drugs 
can still rapidly leak into the systemic circulation. This has been observed in many studies in 
small animals (60–62) and with immunotherapy in humans, where intratumorally-injected 
cytokines have been measured in the systemic circulation within minutes (63). Such 
systemic dissemination both weakens the potency of the therapy by clearing the drug from 
the tumor and gives rise to systemic inflammatory toxicity.
To promote such “in situ vaccination”, biomaterials have been designed to trap 
immunomodulatory molecules in the tumor environment. For example, slow-release 
particles or hydrogels have been injected peritumorally or intratumorally, to allow local 
permeation of tumors with immunostimulatory drugs released from localized depots. This 
has been demonstrated with biodegradable microspheres releasing IL-12 (62) and hydrogel 
matrices releasing an IL-15 superagonist (64), both of which led to non-toxic but potent 
induction of CD8+ T-cell responses against treated tumors. Such approaches can enable 
otherwise toxic treatments to be safely administered while eliciting systemic anti-tumor 
immunity. For example, anti-CD137 and IL-2 administered directly into solid melanoma 
tumors disseminated into the systemic circulation, inducing systemic inflammation, 
including IL-6 and TNF-α in serum and major weight loss in mice (60). However, 
intratumoral injection of these same immunomodulators covalently anchored to liposomes 
prevented their dissemination outside of the local microenvironment (60, 61), eliminating 
their toxicity and enabling the drugs to remain concentrated at the tumor site for 96 hours 
post injection. These intratumoral immunoliposomes acted as vaccines and elicited systemic 
T-cell responses; mice that rejected treated tumors on one flank could also substantially 
delay the growth of an untreated tumor on the contralateral flank, in the complete absence of 
supporting systemic therapy. Thus, even relatively simple strategies can be employed to 
significantly alter the efficacy and safety of immunotherapeutic drugs in this setting.
Active depots with implantable vaccine scaffolds
The only FDA-approved cancer vaccine to date is Provenge, an autologous cell-based 
therapeutic vaccine against castration-resistant metastatic prostate cancer (65). Although this 
vaccine was shown to extend survival in prostate cancer patients by 4 months, its 
implementation is clinically complex, since peripheral blood is first collected from patients, 
shipped to a cell preparation facility, treated with antigen ex vivo, shipped back to the 
clinical site, and subsequently re-infused into the patient. Clinical trials of related processes 
based on the isolation of precursor cells, differentiation of these cells into dendritic cells in 
vitro, activation and antigen loading of the resulting DCs, and injection as cellular vaccines 
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have also shown promise (66, 67) but with the same logistical concerns. In an attempt to 
harness the power of DC vaccines without the practical limitations of cell therapy, several 
strategies have been developed to create implantable or injectable implants that would 
mimic this series of ex vivo treatment steps directly in patients. The common premise of 
these approaches is to employ a synthetic matrix or scaffold that when placed in vivo (e.g., 
following a minor subcutaneous implantation procedure) would release/present cues in the 
local tissue that enable the processes of attracting, differentiating, activating, and antigen 
loading dendritic cells, which would subsequently traffic to local draining lymph nodes to 
initiate an anti-tumor immune response. This concept leverages a large body of experience 
from the tissue engineering and regenerative medicine field, where biomaterial scaffolds 
designed to attract and program cell fate have been studied for more than 20 years (68). 
These biodegradable scaffolds may release immunomodulatory agents with defined spatial 
and temporal profiles that can be engineered by manipulating the material properties of the 
implant. Multiple agents can be loaded into a single immunomodulatory scaffold, including 
antigen, adjuvant, and cytokine support, and they can be designed to promote cell 
recruitment and modulation within the scaffold itself.
One of the first reports of a DC-programming vaccine system utilized millimeter scale 
polymer rods that released the chemoattractant CCL19 along with tumor lysate as an antigen 
preparation (69). These attractant-releasing implants recruited antigen presenting cells to the 
vaccine site, which correlated with enhanced tumor regression in a therapeutic lung 
carcinoma model. More recently, Ali et al. designed centimeter-scale porous polymer disks 
composed of the same polymer used in resorbable sutures (poly(lactide-co-gyolide) or 
PLGA); these disks were loaded with 3 components: GM-CSF, CpG DNA, and tumor 
lysate, as shown in Figure 1D (70). These scaffolds released GM-CSF to recruit and 
differentiate dendritic cells into the structure and CpG as a danger signal to activate DCs 
internalizing antigens in the tumor lysate. These scaffolds were capable of protecting mice 
from B16F10 melanoma challenge in a prophylactic setting. In a follow up study, this 
scaffold vaccine, in combination with vaccination using irradiated tumor cells transduced to 
express GM-CSF, was shown to also greatly enhance protection relative to non-scaffolded 
vaccines or GM-CSF-producing tumor cell-based vaccination alone in the therapeutic 
setting, results which correlated with enhanced recruitment of plasmacytoid DCs, cross-
presenting CD8+ DCs, and elevated IL-12 production in the scaffold implants (71). In a rat 
glioma model, PLGA scaffold vaccines implanted after partial tumor resection resulted in 
significantly enhanced survival over control blank PLGA matrices (72). Efficacy in this 
model was only seen when scaffolds were placed next to the resection site but not within the 
resection site, highlighting the importance of implantation site for these implantable 
scaffold-based vaccines. Based on these encouraging preclinical results, this promising 
PLGA scaffold vaccine system was recently moved into a first-in-human phase I trial in 
patients with melanoma (73).
A number of strategies have sought to generate an in situ-forming immunomodulatory depot 
that does not require surgical implantation like the PLGA-based scaffolds described above. 
In a recent report, antigen and adjuvant were mixed with chitosan and hydroxyapatite and 
co-injected with crosslinking agent tripolyphosphate and chondroitin sulphate via a two 
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needle aligned injection (74). These two aqueous solutions crosslinked in vivo to form a 
biodegradable hydrogel vaccine that was capable of inducing humoral responses durable for 
more than a year after implantation following a single injection; this type of sustained 
release implant may also be of interest for driving anti-tumor T-cell responses. In a second 
example, Kim et al. demonstrated that biodegradable mesoporous silica rods could 
nonspecifically coalesce to form a scaffold-like structure following subcutaneous injection 
(75). When formulated with GM-CSF, CpG, and antigen, these injectable scaffolds were 
capable of recruiting DCs and priming T-cell responses that were capable of delaying the 
outgrowth of OVA-expressing tumors in a prophylactic setting. While still in early stages of 
preclinical development, these “injectable scaffold” approaches may provide a facile 
strategy to repeatedly prime and boost anti-tumor immunity. Importantly, both implanted 
and injectable matrix-based vaccines are powerful technological platforms for examining the 
importance of timing, dosing, and physical localization of immunostimulatory cues on the 
output immune response, making these systems both potential therapeutics and valuable 
tools for determining how these factors quantitatively influence the immune response.
Conclusions
Although traditional techniques inspired by prophylactic vaccines activate immune 
responses, new vaccine concepts are of interest to overcome tumor antigen tolerance and 
tumor-induced immunosuppression in the setting of advanced cancer and to drive immune 
responses of the appropriate magnitude and quality to treat large metastastic tumor burdens. 
Approaches grounded in engineering methods for creating synthetic materials and 
synthesizing new molecules offer a number of strategies to enhance cancer immunotherapy 
and cancer vaccines in particular, including improving the delivery of vaccine components 
to lymphoid organs, optimally programming activated T-cells to home to tumor sites, 
prolonging immunomodulation of lesions following intratumoral injection, and 
programming sequential events in immunization from a single injectable or implantable 
device. Overall, such engineering-based approaches have shown great promise in pre-
clinical models, and the next few years should see a number of these approaches moved into 
clinical testing in patients.
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Figure 1. 
A schematic showing four strategies for engineering more effective cancer vaccines. In (A), 
vaccines are engineered to drain efficiently to lymph nodes. Particles between 5–50nm drain 
more effectively than particles of other sizes, and molecular vaccines can be engineered to 
bind serum proteins to meet this size criteria for effective lymphatic drainage. In (B), T-cell 
homing to specific sites can be directed by the route of administration. For sites like the lung 
and the gut, engineering of biomaterial carriers may facilitate delivery. Immunomodulatory 
therapies can be introduced directly into the tumor to generate anti-tumor responses, shown 
in (C). Implantable biomaterial scaffolds can be loaded with tumor antigens and 
inflammatory signals to create and in-situ dendritic cell vaccine, shown in (D).
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